In recent years, cell-based therapies targeting the immune system have emerged as promising strategies for cancer treatment. This review summarizes manufacturing challenges related to production of antigen presenting cells as a patient-tailored cancer therapy. Understanding cell-material interactions is essential because in vitro cell culture manipulations to obtain mature antigen-producing cells can significantly alter their in vivo performance. Traditional antigenproducing cell culture protocols often rely on cell adhesion to surface-treated hydrophilic polystyrene flasks. More recent commercial and investigational cancer immunotherapy products were manufactured using suspension cell culture in closed hydrophobic fluoropolymer bags. The shift to closed cell culture systems can decrease risks of contamination by individual operators, as well as facilitate scale-up and automation. Selecting closed cell culture bags over traditional open culture systems entails different handling procedures and processing controls, which can affect product quality. Changes in culture vessels also entail changes in vessel materials and geometry, which may alter the cell microenvironment and resulting cell fate decisions. Strategically designed culture systems will pave the way for the generation of more sophisticated and highly potent cell-based cancer vaccines. As an increasing number of cell-based therapies enter the clinic, the selection of appropriate cell culture vessels and materials becomes a critical consideration that can impact the therapeutic efficacy of the product, and hence clinical outcomes and patient quality of life. From the
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C ancer represents a significant socioeconomic burden, causing 8.2 million deaths worldwide in 2012. [1] [2] [3] [4] By 2030, this burden is expected to nearly double, growing to 21.4 million cases and 13.2 million deaths. 2 In recent years, cell therapy has emerged as a novel, complex, and very promising therapeutic strategy for the treatment of diseases that do not respond to classical pharmaceutical or biopharmaceutical product-based treatments. 5, 6 Targeting the immune system-and not the cancer itself-represents a paradigm shift in oncology and vaccinology. Similarly, chimeric antigen receptor (CAR)-and T-cell receptor-engineered T cells have resulted in a landslide transformation in immunology and adoptive cell transfer. 7 These sophisticated cell products are able to reengage the immune system's anticancer responses, replace damaged tissues, and heal chronic wounds. 8, 9 Considering the magnitude of potential impact, the field of "cancer immunotherapy" was chosen as the "Breakthrough of the Year" by Science magazine in 2013. [10] [11] [12] The global market for cell therapy was valued at approximately US$2.5 billion in 2012 and is expected to reach US$8 billion by 2018. 5 The advance of improved technologies in coming years should further reduce production costs and enhance clinical efficacy. Currently available cancer vaccines include cellbased, protein-based, recombinant live vector (viral or bacterial)-based and nucleic acid-based vaccines. 6, 13 Detailed reports summarizing the state of the art and proposed mechanisms of action of both virus-based and DNA-based cancer immunotherapy products have been published recently elsewhere. [13] [14] [15] [16] Currently, there are more than 1900 studies investigating the clinical efficacy of "cancer vaccines" registered with the US National Institutes of Health website (www.clinicaltrials.gov). Most of these trials are in the phase I/II testing safety/ efficacy stage, with only a small number of trials in phase III (Table 1) . Antitumor vaccination with viable, complex active ingredients such as cells is a complicated, multistep task. 17, 18 The optimal clinical-scale production platform and culture modalities for guaranteeing an effective cell product have yet to be established. Manufacturing and distribution challenges can significantly impact the commercial and clinical viability of personalized medicines such as cell-based immunotherapy products. 6, [13] [14] [15] In the transition from preclinical to clinical studies, changes in scale and culture materials, which may at first sight appear trivial, can drastically change the quality and efficacy of the product. This review addresses the manufacturing challenges related to the production and the characterization of antigen-presenting cell (APC)-based cancer vaccines, with emphasis on the impact of cell culture vessel material selection on resulting cell products. Key bioprocess engineering and materials science considerations associated with the transition from standard polystyrene flask cultures to closed cell culture systems such as fluoropolymer-based cell culture bags are presented. This review summarizes translational efforts to improve current strategies in "'bench-to-bedside" applications for dendritic cell (DC)-based immunotherapies from a materials science and bioprocess engineering perspective.
APC-BASED CANCER VACCINES
The development of cell-based cancer vaccines originated with the concept of exploiting the potential of APCs to trigger the immune system. APCs are uniquely qualified to initiate a specific and targeted immune reaction against the presented tumor-associated antigens. 17, 19 In vivo, DCs act as the "professional" and most potent APCs of the immune system. 20 The antigens used in cancer vaccines are typically derived either from the patient's own tumor or are presented to the cells as a recombinant tumorassociated antigen, which may be fused to an adjuvant protein for codelivery.
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Generating tumor-specific APCs in vitro
In vitro, several cell types can be used as progenitor cells to obtain APCs that are phenotypically similar to DCs. [21] [22] [23] [24] [25] Peripheral blood mononuclear cells (PBMCs) and CD341 hematopoietic progenitor cells have been used as sources for DC generation, but monocytes remain the most commonly used progenitor cell type. [26] [27] [28] [29] [30] Monocytes can be induced to generate DCs via addition of differentiationinducing cytokines, typically interleukin (IL)-4 and granulocyte-macrophage colony-stimulating factor, 31, 32 during 3 to 7 days in culture. 33 Cell maturation can be achieved via the addition of a cocktail of inflammatory cytokines and/or toll-like receptor agonists, such as tumor necrosis factor-a, prostaglandin E2, IL-6, lipopolysaccharide and polyinosinic:polycytidylic acid in the final 2 days of culture. 24, [34] [35] [36] [37] [38] [39] [40] [41] During this time period, patient-specific tumor-associated antigens may be added to 
Sipuleucel-T
Sipuleucel-T was the first and so far only Food and Drug Administration-approved cell-based cancer vaccine. This product was developed by Dendreon Corp. Sipuleucel-T is intended as a first-line treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer in patients that no longer respond to conventional hormone therapy. 8, 18, 43, 44 Sipuleucel-T is generated from the patient's own peripheral blood mononuclear cellss, which are subsequently enriched for APCs 16 and exposed to a fusion protein comprised of prostatic acid phosphatase and granulocyte macrophage colony-stimulating factor. 17, 18, 45 The cells are reinfused into the patients within 3 days of the initial leukapheresis. 16, 45 The efficacy of this cell-based immunotherapy was first reported in the landmark phase III IMPACT trial. 19, 45 There, patients received a total of three infusions of the APCs generated in vitro using a fully closed fluoropolymer cell culture bag system. Patients treated with sipuleucel-T had a 4-month overall survival benefit compared to patients infused with the placebo. Despite this and other recent achievements, 16, 17 the precise immunologic mechanisms of action underlying this therapeutic effect are challenging to assess and therefore still unclear. A number of studies have compared traditional polystyrene flask cultures for adherent cells to fluoropolymerbased bag systems, as summarized in Table 2 . As a prominent example, sipuleucel-T was manufactured in fluoropolymer bags (Saint-Gobain) composed of an FEP copolymer. 45, 73 Overall, a paradigm shift can be observed over the past decade, and current best practice methods no longer strictly associate the efficient clinical-scale production of both immature and mature DCs with their adherence to surfaces. Both for adherent and suspension cell cultures, the culture vessel selected may directly or indirectly impact the cues provided from the microenvironment via chemical and mechanical stimuli (Fig. 1 ). The gas permeability of the cell culture vessel can change parameters such as the dissolved oxygen concentration, the pH, and the osmolarity of the cell culture medium. The physicochemical properties of the culture material can affect the type, amount, and conformation of proteins and other medium components adsorbing to the culture vessel. The topography and stiffness of the culture vessel can change cell interactions with the surface, in addition to changing shear forces applied to cells during handling. All of these factors can significantly change the cell microenvironment, potentially synergistically, and alter product quality.
CLOSING THE MANUFACTURING PROCESS: SWITCHING Mo-DC CULTURE FROM POLYSTYRENE TO FLUOROPOLYMER SURFACES Polystyrene-based flask or multiwell cultures
Polystyrene has been traditionally used for cell culture since the 1960s. 74, 75 To support the culture of anchoragedependent cells, the hydrophobic polystyrene must usually be surface treated to render it more hydrophilic and thereby facilitate cell adhesion and spreading in culture conditions. 76, 77 This treatment is proprietary to each commercial manufacturer, but reportedly typically consists of a plasma treatment, which produces additional hydroxyl, carboxyl, and aldehyde groups on the culture surface.
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Battiston and colleagues 78 compared tissue culture polystyrene surfaces from three different companies (Sarstedt, Wisent Corp., and Becton Dickinson) and found marked differences in protein adsorption, surface wettability, and monocyte retention following 7 days of culture. This study and others underline the frequently underreported observation that the choice of tissue culture polystyrene from different manufacturers can lead to significant disparities in terms of protein adsorption and cell spreading characteristics. [79] [80] [81] Given the ubiquitous presence of proteins in animal cell culture media, protein adsorption likely plays a key role in determining cell adhesion to surfaces. Cell surface adhesion is in fact thought to be largely mediated by proteins adsorbed to the surfaces, rather than the surfaces themselves.
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Polyolefin-and fluoropolymer-based bag cell culture systems
In contrast to the more rigid polystyrene-based cell culture plastics such as multiwell plates or T-flasks commonly found in most cell culture laboratories, cell culture bags are made of more flexible polymers, including polyolefins and fluoropolymers. The materials of fabrication of examples of closed systems used to scale up DC production are listed in Table 3 . The most commonly known examples of polyolefins include polyethylene and polypropylene. Polyolefin-based cell containers have been tested for both in vitro culture and storage of CD341 cells, platelets, DCs, and T cells. 60, 66, 67, 72, [84] [85] [86] In the case of monocyte-derived APCs, different monocyte isolation methods may alter the composition of "contaminating" cell populations and proteins entrained with the monocytes seeded, which may in turn impact the propensity of monocytes to adhere to surfaces and to differentiate into APCs. Fluoropolymers are a family of high-performance plastics consisting of fully or partially fluorinated monomers. Many of these polymers are linear and with a backbone of carbon-carbon bonds and pendant carbon-fluorine bonds. The carbon-fluorine bonds of fluoropolymers directly correlate to the unique physical and chemical properties associated with fluoropolymers including low surface free energy and coefficient of friction, chemical inertness, excellent electrical properties, high thermal stability, and maintenance of physical properties even at cryogenic temperatures-a combination of properties that make them interesting candidates for biomedical applications. Fluoropolymers have found extensive commercial application in the chemical, electronic, automotive, and construction industries and, with the exception of PTFE, are meltextrudable thermoplastics that can be processed using traditional polymer processing methods. 88, 90 Similar to polyolefin-based bag systems, fluoropolymermade bags are transparent, flexible, and permeable to oxygen, nitrogen, and carbon dioxide, allowing gas exchange in cell culture incubators. Fluoropolymers are highly resistant to almost all aggressive chemicals and biologics and remain flexible at temperatures ranging from 22408C to 12058C. Melt-processable fluoropolymers such as FEP and PFA offer an excellent alternative to polystyrene containers because of their thermal stability across a wide range of temperatures and the ability to be processed using melt extrusion or thermoforming methods. 91, 92 Certain fluoropolymer bags are also suitable for cell cryopreservation.
BIOPROCESSING AND SCALE-UP CONSIDERATIONS IN BAG CULTURE SYSTEMS Translating cell cultures to clinical scale
Manufacturing cells for immunotherapy at a clinical scale has traditionally been performed in "open" polystyrenebased vessels both for adherent or suspension cell cultures. Open cell culture systems require the "opening" of flasks or plates for media changes and other cell culture manipulations. 93, 94 To decrease the risk of product contamination and by individual operators and to facilitate the scale-up or scale-out and automation of the cell production, "closed" culture systems are thus generally preferred by regulatory authorities to comply with current good manufacturing standards. 23, 33, 42 Scaling up flask-based cultures often starts with Tflasks and then progresses to layered polystyrene culture systems, usually using up to eight units in one incubator per patient. 95 Closed or "functionally closed" culture systems that facilitate scale-up have been developed for certain cell types and applications of interest, such as Mo-DC production (Table 3) , CAR-modified T cells, or mesenchymal stem/stromal cells for tissue regeneration or graftversus-host disease therapy. 95, 96 The implementation of current good manufacturing practices-compliant closed systems such as bioreactor bags reduces the risks of contamination and improves the overall connectivity between different units of the cultures at an industrial scale. Important considerations when transitioning from open systems such as polystyrene flasks to bag-based closed systems are summarized in the following paragraphs and in Fig. 2 , including mass transfer, handling, and processing.
Mass transfer considerations
The culture surface area in most commonly used tissue culture flasks ranges from 25 cm 2 to 225 cm 2 . The recommended fill volume typically corresponds to a liquid height of 2 to 3 mm. 97 This gas/liquid interface is a limiting factor in the scale-up of cell culture systems, as gas exchange almost exclusively occurs via the vented screw cap of the flask. [98] [99] [100] To maintain this level of medium in the presence of evaporation, frequent media changes are necessary, which in turn increases costs of reagents and labor and the probability of contamination. Thus, a variety of gas-permeable bag cell culture containers with low water evaporation rates have been made available to the marketing sizes up to approximately 2 L fill volume (Table 3) . 97, 99, 101, 102 In addition, these devices allow mass transfer through both the upper and the lower surface area of the bags. 97, 99, [101] [102] [103] The choice of plastic for a closed cell culture system, in which product is not exposed to the room environment, has a significant impact on mass transfer of oxygen, carbon dioxide, and water. As can be seen in Fig. 3 , typical plastics used in life science applications have gas permeability and water permeability constants that span three orders of magnitude. Permeability constants are affected by two major materials science parameters: the free volume of a polymer and the chemical compatibility between the polymer and the permeant (e.g., oxygen or water). The free volume of a polymer is the molecular "space" between polymer chains. The effect of the free volume can be directly observed in Fig. 3 by comparing high-density polyethylene (HDPE) and low-density polyethylene. Manufacturers of polyethylene manipulate the free volume of their polyethylene resins by controlling the number and length of branches of the main polyethylene chain during synthesis. Low-density polyethylene has more and longer branches, leading to more free volume and, consequently, higher gas and water permeability than high-density polyethylene. Rubbers are also defined by their higher free volume and tend to have high permeability constants. The impact of chemical compatibility can be observed in Fig. 3 when considering the water permeability constants. Water is a polar solvent and is more chemically compatible with polar plastics such as ethylene-vinyl acetate, leading to higher permeability values. The presence of plasticizers and other fillers can also affect permeability and water vapor transmission through a polymer matrix as shown in Fig. 3 for polyvinyl chloride versus plasticized polyvinyl chloride. In instances where a closed cell culture system requires a plastic material with poor permeability, sterilizing-grade vent filters can be used, as typically employed in polystyrene T-flasks.
Leachables and extractables
In shifting from polystyrene-based flask cultures to bag systems, the profile of leachables and extractables is expected to change considerably due to the different types and quantities of plasticizers used in the manufacture of "plastic" disposable systems for cell culture. Leachables and extractables found in polystyrene or ethylene-vinyl acetate polymers can have unknown, and both negative or positive effects on cell processing. 107, 108 Because extractables' profiles may vary from lot to lot for some materials, extractables can reduce cell culture process reproducibility. FEP is extruded as a virgin resin and does not contain any additives or plasticizers. As a fully fluorinated polymer, it has very high inherent stability, and there are no modifiers or other content to leach out in water or other solvents. Consequently, extractables are typically at or below detection limits for FEP.
Handling and processing
Cell culture bags can be used as stand-alone units or as single-use, wave-rocking programmable bioreactor systems. 33, 103 Cell feeding or splitting is made redundant by higher volumes of media in increasing bag sizes, and cell manipulation events are minimized by aseptic tubing connection technologies (e.g., Luer lock, sterile docking, tubing welding). 42 Typical unit operations used to manufacture autologous cell therapy products include (1) cell isolation/enrichment; (2) cell culture and, if applicable, modification; (3) concentration/washing; (4) product purification; (5) formulation and filling; and (6) cryopreservation. 42, 94 In the case of genetically modified APCs or other cell therapy products such as CAR-T cells, closed culture systems decrease risks of contamination and exposure of personnel to viral constructs and other potentially pathogenic agents. Cell culture bags and other functionally closed systems can also facilitate the automation of most of these processing steps. Sterile docking (using tube welders) is commonly used in order to infuse or withdraw fluids from cell culture bags using pumps. Alternatively, fluid handling can be performed manually (e.g., using syringes) through a variety of ports such as needle access ports, spike ports, or fluid loss valves.
Effect of culture surfaces on cell fate in vitro
The effect of culture surfaces on cell fate during an extended period of time ex vivo is still largely unknown. Several reports document the loss of progenitor cells and cellular properties related to a cell's "stemness" on planar surfaces displaying nonphysiologic properties. [109] [110] [111] Interestingly, Yang and colleagues 112 showed that stem cells not only respond to mechanical cues presented to them by their microenvironment, but also possess a mechanical memory that plays a role in governing cell fate decisions. 113 Polystyrene, the most commonly used material for cell culture vessels, has an elastic modulus of approximately 3 GPa, more than five orders of magnitude stiffer than most cell types. 110, 114 The FEP used in fluoropolymer bags such as those manufactured by Saint-Gobain has an elastic modulus of approximately 500 MPa. By comparison, the elastic modulus experienced by cells in situ in most tissues is four to six orders of magnitude lower. 111, 114, 115 In Fig. 4 , the stiffness of materials commonly used to fabricate cell culture vessels is compared to the stiffness of DCs and other cells or tissues DCs may interact with in vivo. In addition to mechanical properties, the chemical makeup and wettability of culture surfaces directly impact protein adsorption to surfaces and cell-surface interactions. In general, in the presence of proteins present in blood and most cell culture media (e.g., insulin, transferrin, albumin), anchorage-dependent cells attach more readily to hydrophilic materials. 121 The extent of cell adhesion and spreading depends on the type and on the conformation of proteins present on surfaces-a topic that has been extensively reviewed elsewhere. 122 Cell culture vessel surfaces can be surface treated, typically using plasma treatments, to introduce charged functional groups on surfaces, increase surface hydrophilicity, and promote cell adhesion. For example, polystyrene flasks as well as FEP bags are available in "untreated" (hydrophobic) or "treated" (more hydrophilic) versions. Cell culture vessels can also be preincubated with media containing extracellular matrix proteins that mediate cell adhesion. Extracellular matrix precoating of culture vessels can improve antigen uptake 123 and/or maturation 124 of Mo-DCs.
Studies comparing Mo-DC cultures in bag versus flask systems
Most studies comparing Mo-DC cultures in polystyrene flasks (adherence) to hydrophobic bags (suspension) report no marked difference between DCs generated in either system (Table 2 ). Kurlander and colleagues 70 reported that DCs generated in FEP bags yielded cells with a surface marker expression profile that was comparable to adherence cultures on polystyrene surfaces. However, the DCs generated in the FEP bags produced significantly less IL-10 and IL-12 during their maturation, and these differences persisted upon rechallenge after harvest. 70 Elias and colleagues reported that after 6 days of culture in polyolefin coextruded with polystyrene cell culture containers (Opticyte, Baxter International, Inc.; see Table 2 ), DCs no longer expressed CD1a, although they otherwise exhibited a surface phenotype that was comparable to DCs cultured on polystyrene surfaces. These results confirmed a previous observation by Thurner and colleagues. 53, 60 Furthermore, Guyre and colleagues 71 reported that DC cultured in hydrophobic bags (polyolefin coextruded with polystyrene; see Table 2 ) were phenotypically different from those cultured in flasks. However, this did not affect their capacity to present antigens, as expression of both major histocompatibility complex class I and class II molecules was consistently high. While the implications of these findings have yet to be determined, these minor differences should be considered when selecting the culture vessel for immunotherapy. Not all cell container systems may be equally suited for generating the optimal cell-based product targeting a specific clinical indication. Stringent potency assays will be necessary to define the essential quality control and release criteria ensuring the generation of efficacious cell therapy products. 
OUTLOOK: HOW TO IMPROVE CLINICAL EFFICACY OF CELL-BASED IMMUNOTHERAPY PRODUCTS?
The approval of sipuleucel-T by the Food and Drug Administration in 2010 was recognized as an important proof of concept that paved the way for industrial production of cell-based cancer vaccines. 12 Patients infused with sipuleucel-T demonstrated a significant increase in median survival time by 4 months compared to placebo controls. 45 However, no differences in the time to disease progression were observed. In addition, no tumor regression or reduction in tumor burden could be measured in treated patients, resulting in novel investigations of the mode and mechanism of action of sipuleucel-T. 14 Recent findings demonstrated that patients receiving sipuleucel-T showed increased levels of secondary self-antigens, an immunologic response known as antigen spread. 125 Several approaches are being investigated to achieve the full potential of DC-based vaccines, including increasing the potency of the DCs, targeting the DCs to the tumors, and inhibiting endogenous mechanisms that limit tumorspecific immune responses.
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Recent findings also raised questions related to the migratory capacities of the administered APCs to home toward the lymph nodes, a crucial step for the efficient activation of CD41 and CD81 T lymphocytes. Reportedly, only 5% of the injected cells reached the lymph node, which may have contributed to the suboptimal success of pioneer immunotherapy products. 126 The reasons for this impaired homing capacity remain unclear. However, the type, number, and source used for APCs, as well as the site and frequency of injection, may be cornerstones for improving the performance of cell-based products. 13, 14, 43, 44, 93, 126, 127 In addition, the in vitro cell culture may adversely regulate cell adhesion and migratory surface receptors, further highlighting the importance of understanding cell-material and cell-surface interactions. Previous studies aimed to identify the optimal culture system (bags vs. flasks), culture surface (polystyrene vs. polyolefins vs. fluoropolymers), and time of culture ("fast" DCs vs. conventional). 25, 128 Rather than stand-alone therapies, combinatorial approaches employing both cell-based vaccines and potent but safe adjuvant molecules suppressing the tumor's tolerance mechanisms will be essential for future cancer care. 12, 130 Improved immune-monitoring strategies and an extended repertoire of predictive biomarkers will be necessary to yield a better understanding of the optimal timing and sequence of administering immunomodulatory agents.
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CONCLUSIONS
The combination of conventional treatments with novel products such as cell-based therapeutics may augment current strategies for patient healthcare. Currently, a wide range of cell types, including hematopoietic stem cells, multipotent progenitors, and fully differentiated effector cells, is manufactured and tested for cell therapy applications. The results of many recent clinical trials, however, remain ambivalent as to the efficacy and potency of these cell products. Additive or synergistic effects between the administered cell products and existing drug-based therapies that lead to desirable clinical outcomes are being explored, but the mechanisms that may lead to these effects remain little understood. Researchers have only recently started to explore the impact of changing cell culture "plastics" for clinical-scale production of cell therapy products. Differences in mass transfer and mechanical and chemical properties can have drastic effects on cell fate. Selecting the appropriate cell cultivation system is thus fundamental in the design and development of cell production strategies. Although this review focused on studies in the immunotherapy field, other therapeutic cell types are being manufactured in the same or similar culture vessels. The handling, processing, and material properties considerations presented in this review will impact the outcome of other therapeutic cell manufacturing processes. Strategically designed cell culture systems will pave the way for the generation of potent cell-based cancer vaccines and other therapeutic cell types.
